Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 18 19 20 21 22 … 50 Next »

Systemic drug survival rates in psoriasis patients

Threaded Mode
Systemic drug survival rates in psoriasis patients
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 57,829
Threads: 3,578
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 1
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Wed-23-11-2016, 20:55 PM
This study looked at drug survival rates of systemic treatments in psoriasis patients.

Treatments involved:
Fumaric acid esters (FAE)
Methotrexate (MTX)
Acitretin (ACI)
Cyclosporine A (CyA)
Adalimumab (ADA)
Etanercept (ETA)
Infliximab (INF)
Ustekinumab (UST)

Quote:
Background and objectives:
Moderate-to-severe psoriasis frequently requires long-term systemic therapy. Reflecting efficacy, safety, and treatment satisfaction, drug survival is an indicator of therapeutic success. The objective of the present study was to assess drug survival rates and reasons for discontinuation of fumaric acid esters (FAE), methotrexate (MTX), acitretin (ACI), cyclosporine A (CyA), adalimumab (ADA), etanercept (ETA), infliximab (INF), and ustekinumab (UST) in patients with moderate-to-severe psoriasis.

Patients and methods:
We performed a retrospective analysis of 373 patients who had received a total of 696 treatment courses at a German university hospital in the period 1/2003–5/2014.

Results:
The crude probability of survival was highest for UST, followed by ADA, ETA, INF, FAE, MTX, ACI, and CyA. In multivariate regression analysis using FAE as reference, hazard ratios (HR) for discontinuation were 0.14 (95 % confidence interval: 0.06–0.35) for UST, 0.43 (0.26–0.73) for ADA, 2.11 (1.14–3.91) for ACI, and 3.26 (1.44–7.39) for CyA. INF showed longer survival when combined with MTX (HR 2.87, 1.21–6.81). Traditional systemic antipsoriatic agents as well as INF were most frequently discontinued due to adverse events; all other biologics, due to inefficacy with respect to cutaneous lesions.

Conclusions:
Drug survival rates should be integrated into therapeutic decisions in order to provide patients with an optimal long-term strategy.

Source: onlinelibrary.wiley.com

*Funding unknown
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Bio's for psoriasis in HIV patients Fred 1 716 Sun-12-03-2023, 16:02 PM
Last Post: Caroline
News Cosentyx better than nb-UVB in treating patients with new onset psoriasis Fred 2 993 Fri-13-01-2023, 21:08 PM
Last Post: Fred
News Increased Risk of Suicidality in Patients with Psoriasis Fred 3 1,277 Sun-28-08-2022, 10:56 AM
Last Post: Fred
News Metabolic syndrome more common in patients with psoriatic arthritis Fred 6 3,836 Fri-01-07-2022, 20:51 PM
Last Post: Caroline
News Effectiveness of (IL)-17A to other biologics in patients with psoriasis Fred 3 1,394 Fri-01-07-2022, 11:57 AM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode